undamentalytics Newsletter
Sign in

Niagen Bioscience, Inc. balance sheet

At the end of fiscal 2025, Niagen Bioscience, Inc. had total assets of $106m, total liabilities of $29.9m and shareholders' equity of $76.5m. It held $64.8m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Jan 20112011Dec 20112012Dec 20122013Dec 20132014Jan 20152015Jan 20162016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents2———————231917282027456567
Receivables112122654235858109
Inventory135248868121214151592021
Total current assets558610171657373432494750649798
Total assets76991219206342403858545568106107
Accounts payable12313664101091010109119
Total current liabilities135351098141516181821182015
Short-term debt————020——————————
Long-term debt————230——————————
Total debt—000550—010—000000
Total liabilities——53813109152022262527223024
Shareholders' equity5346451054272016322928467783
Shares outstanding—————36m38m55m55m60m62m68m75m75m77m80m79m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: NAGE vs ZVRANAGE vs NAIIHRTX vs NAGEETON vs NAGE

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Niagen Bioscience, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Niagen Bioscience, Inc.